Cross-talk between the thyroid and liver: A new target for nonalcoholic fatty liver disease treatment

被引:28
|
作者
Huang, Yue-Ye [1 ]
Gusdon, Aaron M. [3 ]
Qu, Shen [1 ,2 ]
机构
[1] Tongji Univ, Shanghai Peoples Hosp 10, Dept Endocrinol & Metab, Sch Med, Shanghai 200072, Peoples R China
[2] Nanjing Med Univ, Dept Endocrinol & Metab, Nanjing 210029, Jiangsu, Peoples R China
[3] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA
关键词
Thyroid hormone; Thyroid hormone receptor; Nonalcoholic fatty liver disease; Obesity; HORMONE RECEPTOR-BETA; HEPATIC INSULIN-RESISTANCE; BONE-MINERAL DENSITY; BROWN ADIPOSE-TISSUE; AGONIST GC-1; ALPHA-GENE; TR-BETA; METABOLIC SYNDROME; NUCLEAR RECEPTOR; BODY-WEIGHT;
D O I
10.3748/wjg.v19.i45.8238
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) has been recognized as the most common liver metabolic disease, and it is also a burgeoning health problem that affects one-third of adults and is associated with obesity and insulin resistance now. Thyroid hormone (TH) and its receptors play a fundamental role in lipid metabolism and lipid accumulation in the liver. It is found that thyroid receptor and its isoforms exhibit tissue-specific expression with a variety of functions. TR beta 1 is predominantly expressed in the brain and adipose tissue and TR beta 2 is the major isoform in the liver, kidney and fat. They have different functions and play important roles in lipid metabolism. Recently, there are many studies on the treatment of NAFLD with TH and its analogues. We review here that thyroid hormone and TR are a potential target for pharmacologic treatments. Lipid metabolism and lipid accumulation can be regulated and reversed by TH and its analogues. (C) 2013 Baishideng Publishing Group Co., Limited. All rights reserved.
引用
收藏
页码:8238 / 8246
页数:9
相关论文
共 50 条
  • [21] Treatment strategies in nonalcoholic fatty liver disease
    Herbert Tilg
    Arthur Kaser
    Nature Clinical Practice Gastroenterology & Hepatology, 2005, 2 : 148 - 155
  • [22] Antioxidant treatment in nonalcoholic fatty liver disease
    Celikbilek, Mehmet
    Dogan, Serkan
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2014, 25 (04): : 468 - 468
  • [23] Which treatment for nonalcoholic fatty liver disease?
    Moscatiello, S.
    Marzocchi, R.
    Villanova, N.
    Bugianesi, E.
    Marchesini, G.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2008, 8 (08) : 767 - 775
  • [24] Prevention and treatment of nonalcoholic fatty liver disease
    Targher, Giovanni
    Bellis, Alessandro
    Fornengo, Paolo
    Ciaravella, Francesca
    Pichiri, Isabella
    Perin, Paolo Cavallo
    Trimarco, Bruno
    Marchesini, Giulio
    DIGESTIVE AND LIVER DISEASE, 2010, 42 (05) : 331 - 340
  • [25] Treatment of diabetes in nonalcoholic fatty liver disease
    Bodis, K.
    Roden, M.
    DIABETOLOGE, 2016, 12 (07): : 486 - 493
  • [26] Nonalcoholic Fatty Liver Disease and Obesity Treatment
    Katherine T. Brunner
    Cameron J. Henneberg
    Robert M. Wilechansky
    Michelle T. Long
    Current Obesity Reports, 2019, 8 : 220 - 228
  • [27] Nonalcoholic Fatty Liver Disease and Obesity Treatment
    Brunner, Katherine T.
    Henneberg, Cameron J.
    Wilechansky, Robert M.
    Long, Michelle T.
    CURRENT OBESITY REPORTS, 2019, 8 (03) : 220 - 228
  • [28] New treatments for nonalcoholic fatty liver disease
    Harrison S.A.
    Current Gastroenterology Reports, 2006, 8 (1) : 21 - 29
  • [29] Nonalcoholic Fatty Liver Disease: The New Epidemic
    Bessette, Michael
    PHYSICIAN ASSISTANT CLINICS, 2021, 6 (04) : 667 - 675
  • [30] Nonalcoholic fatty liver disease: new treatments
    Hardy, Timothy
    Anstee, Quentin M.
    Day, Christopher P.
    CURRENT OPINION IN GASTROENTEROLOGY, 2015, 31 (03) : 175 - 183